SunPharmaAnlaysis.docx - SUN PHARMACEUTICAL INDUSTRIES LIMITED Case Study Business Growth Analysis Contents Introduction.2 History and Growth.2 Vision

SunPharmaAnlaysis.docx - SUN PHARMACEUTICAL INDUSTRIES...

This preview shows page 1 - 4 out of 15 pages.

SUN PHARMACEUTICAL INDUSTRIES LIMITED Case Study – Business Growth Analysis
Image of page 1
Contents Introduction ................................................................................................................................................. 2 History and Growth ................................................................................................................................. 2 Vision & Mission ...................................................................................................................................... 2 Share Holding Pattern .............................................................................................................................. 3 Sun Pharma and Peers ............................................................................................................................. 3 Financials ..................................................................................................................................................... 4 India Pharma sector - Sun Pharma .......................................................................................................... 6 Looking Ahead ............................................................................................................................................. 6 SWOT ANALYSIS ....................................................................................................................................... 8 Strengths: ............................................................................................................................................ 8 Weakness: ............................................................................................................................................ 8 Opportunities: ..................................................................................................................................... 8 Threats: ................................................................................................................................................ 8 Appendix 1.0 .............................................................................................................................................. 10 Key Acquisitions ..................................................................................................................................... 10 Appendix 1.1 .............................................................................................................................................. 11 Consolidate Balance Sheet .................................................................................................................... 11 Consolidate Profile and Loss Statement ................................................................................................. 12 Calculations ........................................................................................................................................... 13 BIBLIOGRAPHY ........................................................................................................................................... 13 1 | P a g e
Image of page 2
Introduction Sun Pharmaceutical Industries Ltd., headquartered in Mumbai, India, is a Large Cap company operating in Pharmaceuticals and health care sector. It primarily manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs). It has portfolio of more than 2000 products covers multiple dosage forms, including tablets, capsules, injectable, ointments, creams, liquids and specialty APIs, including steroids, peptides and anti-cancer products. It is the fifth largest Pharmaceutical company in the world with market cap of US$ 22 billion 1 and have global presence in over 100 countries, being India and US are two predominant markets, that accounts to 70% of the company’s revenue. It is listed on both Bombay and National Stock Exchanges of India. Our study deals in understanding company’s growth for period between 2013 - 17 FY and also perform SWOT analysis to understand company’s future outlook. History and Growth Sun Pharmaceuticals was established by Mr. Dilip Shanghvi in the year 1983 at Vapi, with five products to treat psychiatry ailments. In 1987, Products that are used in cardiology were introduced, Monotrate and Angizem, few of the first products launched at that time has since become one of their largest selling products. In 1994, Sun Pharma was listed on the Bombay and National stock exchanges; an issue of 55crore rupees, with Equity Share of Face value 10 rupees was offered at a 140 rupees premium, the issue was oversubscribed 55 times. In the year 1997, the company's headquarters was shifted to Mumbai, India's commercial capital. Also, they began the first of their international acquisitions with an initial $7.5 million investment in Caraco, Detroit. The company has a tremendous track record of 20 successful acquisitions 1 so far, with acquisition of Ranbaxy in 2014 became India’s 1st and world’s 5th largest generic drug making company. Tally at the end of 2017 Presence in over 100 countries 41 manufacturing sites Portfolio of more than 2,000 products 30,000+ global employee base Vision & Mission Reaching People and Touching Lives Globally as a Leading Provider of Valued Medicines. Drive Long Term Growth Create Sustainable Revenue Streams by enhancing share of specialty business globally and ensuring timely approval of products from regulatory bodies.
Image of page 3
Image of page 4

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture